Published in Molecular Medicine Reports
Autosomal dominant polycystic kidney disease (ADPKD), a common disease with a high incidence ratio of between 1/400 and 1/1,000 individuals, often results in kidney failure and even mortality. However, there are relatively few effective treatments available, and treatment is limited to lifelong hemodialysis or kidney transplant. Our previous studie...
Published in Clinical journal of the American Society of Nephrology : CJASN
Published in Diagnostics
Total Kidney Volume (TKV) is essential for analyzing the progressive loss of renal function in Autosomal Dominant Polycystic Kidney Disease (ADPKD). Conventionally, to measure TKV from medical images, a radiologist needs to localize and segment the kidneys by defining and delineating the kidney’s boundary slice by slice. However, kidney localizatio...
Published in Pharmaceutics
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic model for nimotuzumab and to identify demographic an...
Published in Canadian Journal of Kidney Health and Disease
Background: Ureteroscopy is a minimally invasive treatment option for upper tract stones. The distorted kidney anatomy in patients with autosomal dominant polycystic kidney disease (ADPKD) may place them at higher risk for ureteroscopic complications. Objective: To compare the 30-day risk of ureteroscopic complications between patients with and wit...
Published in Nutrients
The excess intake of dietary sodium is a key modifiable factor for reducing disease progression in autosomal dominant polycystic kidney disease (ADPKD). The aim of this study was to test the hypothesis that the scored salt questionnaire (SSQ; a frequency questionnaire of nine sodium-rich food types) is a valid instrument to identify high dietary sa...
Published in Canadian Journal of Kidney Health and Disease
Background: Recent years have witnessed an encouraging expansion of knowledge and management tools in the care of patients with autosomal dominant polycystic kidney disease (ADPKD), including measurement of total kidney volume as a biomarker of disease progression, stringent blood pressure targets to slow cyst growth, and targeted treatments such a...
Published in Cureus
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the commonest inherited disorder of the kidneys. A vasopressin V2-receptor antagonist (tolvaptan) was recently approved for the treatment of ADPKD. This study aims to analyze the safety and tolerability of tolvaptan for the management of ADPKD patients in a real-world setting. Me...
Published in Canadian journal of kidney health and disease
Le protocole de cette revue systématique n’a pas été enregistré.
Published in International Journal of Molecular Sciences
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inheritable cause of end stage renal disease and, as of today, only a single moderately effective treatment is available for patients. Even though ADPKD research has made huge progress over the last decades, the precise disease mechanisms remain elusive. However, a wide variety...
